193 related articles for article (PubMed ID: 38611638)
1. Three-Dimensional Structure of Novel Liver Cancer Biomarker Liver Cancer-Specific Serine Protease Inhibitor Kazal (LC-SPIK) and Its Performance in Clinical Diagnosis of Hepatocellular Carcinoma (HCC).
Lu F; Ott C; Bista P; Lu X
Diagnostics (Basel); 2024 Mar; 14(7):. PubMed ID: 38611638
[TBL] [Abstract][Full Text] [Related]
2. Liver Cancer-Specific Serine Protease Inhibitor Kazal Is a Potentially Novel Biomarker for the Early Detection of Hepatocellular Carcinoma.
Lu F; Shah PA; Rao A; Gifford-Hollingsworth C; Chen A; Trey G; Soryal M; Talat A; Aslam A; Nasir B; Choudhry S; Ishtiaq R; Sanoff H; Conteh LF; Noonan A; Hu KQ; Schmidt C; Fu M; Civan J; Xiao G; Lau DT; Lu X
Clin Transl Gastroenterol; 2020 Dec; 11(12):e00271. PubMed ID: 33512798
[TBL] [Abstract][Full Text] [Related]
3. Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease.
Caviglia GP; Nicolosi A; Abate ML; Carucci P; Rosso C; Rolle E; Armandi A; Aneli S; Olivero A; Risso A; Ribaldone DG; Fermer C; Saracco GM; Gaia S; Bugianesi E
Curr Oncol; 2022 Jul; 29(8):5457-5465. PubMed ID: 36005169
[TBL] [Abstract][Full Text] [Related]
4. Long noncoding RNA MyD88 functions as a promising diagnostic biomarker in hepatocellular carcinoma.
Wang Z; Gao P; Sun W; Rehman AU; Jiang J; Xu S; Xue C; Zhu C; Qin X
Front Endocrinol (Lausanne); 2023; 14():938102. PubMed ID: 36793272
[TBL] [Abstract][Full Text] [Related]
5. Optimisation of quantitative miRNA panels to consolidate the diagnostic surveillance of HBV-related hepatocellular carcinoma.
Tat Trung N; Duong DC; Tong HV; Hien TTT; Hoan PQ; Bang MH; Binh MT; Ky TD; Tung NL; Thinh NT; Sang VV; Thao LTP; Bock CT; Velavan TP; Meyer CG; Song LH; Toan NL
PLoS One; 2018; 13(4):e0196081. PubMed ID: 29672637
[TBL] [Abstract][Full Text] [Related]
6. Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase.
Yang JD; Dai J; Singal AG; Gopal P; Addissie BD; Nguyen MH; Befeler AS; Reddy KR; Schwartz M; Harnois DM; Yamada H; Gores GJ; Feng Z; Marrero JA; Roberts LR
Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1085-1092. PubMed ID: 28258053
[No Abstract] [Full Text] [Related]
7. Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients.
Gatselis NK; Tornai T; Shums Z; Zachou K; Saitis A; Gabeta S; Albesa R; Norman GL; Papp M; Dalekos GN
World J Gastroenterol; 2020 Sep; 26(34):5130-5145. PubMed ID: 32982114
[TBL] [Abstract][Full Text] [Related]
8. Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies.
Tayob N; Corley DA; Christie I; Almers L; Rahal AK; Richardson P; White DL; Davila J; Kanwal F; El-Serag HB
Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1443-1450.e6. PubMed ID: 32768590
[TBL] [Abstract][Full Text] [Related]
9. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma.
Jia J; Ga L; Liu Y; Yang Z; Wang Y; Guo X; Ma R; Liu R; Li T; Tang Z; Wang J
Front Immunol; 2022; 13():923031. PubMed ID: 35924241
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Diagnostic Efficiency of Alpha-Fetoprotein in Patients with Liver Cirrhosis and Hepatocellular Carcinoma: Single-Center Experience.
Mehinovic L; Islamagic E; Husic-Selimovic A; Kurtovic-Kozaric A; Vukobrat-Bijedic Z; Suljevic D
Open Access Maced J Med Sci; 2018 Sep; 6(9):1668-1673. PubMed ID: 30337985
[TBL] [Abstract][Full Text] [Related]
11. GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients.
Schotten C; Ostertag B; Sowa JP; Manka P; Bechmann LP; Hilgard G; Marquardt C; Wichert M; Toyoda H; Lange CM; Canbay A; Johnson P; Wedemeyer H; Best J
Pharmaceuticals (Basel); 2021 Jul; 14(8):. PubMed ID: 34451832
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of serum AFP and DCP levels in the diagnosis of early-stage HBV-related HCC under different backgrounds.
Song T; Wang L; Xin R; Zhang L; Tian Y
J Int Med Res; 2020 Oct; 48(10):300060520969087. PubMed ID: 33135527
[TBL] [Abstract][Full Text] [Related]
13. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis.
Best J; Bechmann LP; Sowa JP; Sydor S; Dechêne A; Pflanz K; Bedreli S; Schotten C; Geier A; Berg T; Fischer J; Vogel A; Bantel H; Weinmann A; Schattenberg JM; Huber Y; Wege H; von Felden J; Schulze K; Bettinger D; Thimme R; Sinner F; Schütte K; Weiss KH; Toyoda H; Yasuda S; Kumada T; Berhane S; Wichert M; Heider D; Gerken G; Johnson P; Canbay A
Clin Gastroenterol Hepatol; 2020 Mar; 18(3):728-735.e4. PubMed ID: 31712073
[TBL] [Abstract][Full Text] [Related]
14. Latent transforming growth factor-beta binding protein-1 in circulating plasma as a novel biomarker for early detection of hepatocellular carcinoma.
Cao B; Yang L; Rong W; Feng L; Han N; Zhang K; Cheng S; Wu J; Xiao T; Gao Y
Int J Clin Exp Pathol; 2015; 8(12):16046-54. PubMed ID: 26884881
[TBL] [Abstract][Full Text] [Related]
15. TEMs but not DKK1 could serve as complementary biomarkers for AFP in diagnosing AFP-negative hepatocellular carcinoma.
Mao L; Wang Y; Wang D; Han G; Fu S; Wang J
PLoS One; 2017; 12(9):e0183880. PubMed ID: 28902891
[TBL] [Abstract][Full Text] [Related]
16. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease.
Beale G; Chattopadhyay D; Gray J; Stewart S; Hudson M; Day C; Trerotoli P; Giannelli G; Manas D; Reeves H
BMC Cancer; 2008 Jul; 8():200. PubMed ID: 18638391
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study.
Ji J; Wang H; Li Y; Zheng L; Yin Y; Zou Z; Zhou F; Zhou W; Shen F; Gao C
PLoS One; 2016; 11(4):e0153227. PubMed ID: 27070780
[TBL] [Abstract][Full Text] [Related]
18. Assessment of high-sensitivity C-reactive protein tests for the diagnosis of hepatocellular carcinoma in patients with hepatitis B-associated liver cirrhosis.
Ma LN; Liu XY; Lu ZH; Wu LG; Tang YY; Luo X; Hu YC; Yan TT; Wang Q; Ding XC; Xie Y
Oncol Lett; 2017 May; 13(5):3457-3464. PubMed ID: 28521452
[TBL] [Abstract][Full Text] [Related]
19. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Cramp M; Jackson S; Ryder S; Price A; Stein K
Health Technol Assess; 2007 Sep; 11(34):1-206. PubMed ID: 17767898
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Significance of hsa-miR-21-5p, hsa-miR-192-5p, hsa-miR-155-5p, hsa-miR-199a-5p Panel and Ratios in Hepatocellular Carcinoma on Top of Liver Cirrhosis in HCV-Infected Patients.
Eldosoky MA; Hammad R; Elmadbouly AA; Aglan RB; Abdel-Hamid SG; Alboraie M; Hassan DA; Shaheen MA; Rushdi A; Ahmed RM; Abdelbadea A; Abdelmageed NA; Elshafei A; Ali E; Abo-Elkheir OI; Zaky S; Hamdy NM; Lambert C
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
